Abstract 1947P
Background
The clinical profiles of recurrent retroperitoneal liposarcoma (RLS) need to be explored. The recurrence patterns of RLS are controversial and ambiguous.
Methods
A total of 138 patients with recurrent RLS were finally recruited in the study. The analysis of overall survival (OS) and recurrence-free survival (RFS) was performed by Kaplan‒Meier analysis. The nomogram model was built to predict the survival status of patients. Univariate and multivariate analysis were performed for the selection of independent prognostic factors that were correlated with OS or RFS.
Results
Among patients, the 1-, 3-, and 5-year OS rates were 70.7%, 35.9% and 30.9%, respectively. The 1-, 3- and 5-year RFS rates of the 55 patients who underwent R0 resection were 76.1%, 50.8% and 34.4%, respectively. The multivariate analysis revealed that resection method, tumor size, status of pathological differentiation, pathological subtypes and recurrence pattern were independent risk factors for OS or RFS. Patients with distant recurrence (DR) pattern usually had multifocal tumors (90.5% vs. 74.7%, P < 0.05); they were prone to experience changes of pathological differentiation (69.9% vs. 33.3%, P < 0.05) and had a better prognosis than those with local recurrence (LR) pattern. R0 resection and combined organ resection favored the survival of patients with DR pattern in some cases.
Conclusions
Patients with DR pattern have a better prognosis, and they may benefit more from aggressive combined resection than those with LR. Classifying the recurrence patterns of RLS provides guidance for individualized clinical management of recurrent RLS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1820P - Cardiovascular effects of androgen receptor signalling inhibitors in the treatment of advanced and metastatic prostate cancer: A systematic review and meta-analysis of randomised controlled trials
Presenter: Omar El-Taji
Session: Poster session 15
1821P - High serum FSH/T ratio as a marker for the development of cardiovascular disease in ADT recipients
Presenter: Jehonathan Pinthus
Session: Poster session 15
1822P - PSMA-alpha targeted radionuclide therapy (TRT) with or without prior PSMA-beta TRT
Presenter: Michael Sun
Session: Poster session 15
1823P - The impact of baseline PSMA PET/CT vs. CT on outcomes of Radium-223 therapy in mCRPC patients
Presenter: Dianne Bosch
Session: Poster session 15
1824P - Treatment patterns among novel hormonal therapy-experienced patients with metastatic castration-resistant prostate cancer
Presenter: Vivek Narayan
Session: Poster session 15
1825P - Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
Presenter: David Goode
Session: Poster session 15
1826P - Lutetium-177-PSMA in pre- and post-taxane mCRPC setting: Results from a phase II clinical trial
Presenter: Emilio Giunta
Session: Poster session 15
1827P - Real-world (RW) overall survival (OS) with enzalutamide (ENZ) and abiraterone acetate (ABI) in patients (pts) with chemotherapy (cx)-naïve metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel George
Session: Poster session 15
1828P - ARX517: A next generation anti-PSMA antibody drug conjugate (ADC) demonstrates notable stability and pharmacokinetic (PK) profile in the ARX517 phase I clinical trial (APEX-01)
Presenter: Scott Tagawa
Session: Poster session 15
1829P - Exposure-safety analyses of talazoparib in combination of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in TALAPRO-2 trial
Presenter: Arun Azad
Session: Poster session 15